Phase I Study of Cetuximab Plus Dasatinib (BMS-354825) in Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2014
At a glance
- Drugs Cetuximab (Primary) ; Dasatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 10 Jun 2017 Biomarkers information updated
- 21 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Apr 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.